Skip to content

Doctors and investors in a meeting
Event has ended

Webinar - Swiss Nordic Bio – Matching Startups with Competent Capital

22.01.2025, 14:00 - 15:00 GMT+01:00

Location: Online, Online

Webinar

Join us to explore how Swiss Nordic Bio connects Nordic startups with competent capital and promotes strategic collaboration in the life science and health tech industries.

This informative webinar highlights insights from Novartis Venture Fund and key players in the Nordic ecosystem. Discover opportunities to strengthen your international position and leverage Zurich’s thriving innovation landscape.

Why Attend?

  • Learn how Swiss Nordic Bio facilitates connections between Nordic startups and investors.
  • Hear reflections and insights from Novartis Venture Fund, Hemispherian, and other industry leaders.
  • Discover new collaboration opportunities through Zurich’s innovation ecosystem.

Practical information

The Norwegian Embassy will offer Norwegian participants a 50% discount on the participation fee in 2025.
Don’t miss this opportunity to gain valuable insights and expand your network. Mark your calendar and register today!

Organisers

BIOTECH NORTH

HEALTHCATALYST AS

Website

INNOVASJON NORGE

NORWAY HEALTH TECH

NORWEGIAN SMART CARE CLUSTER

OSLO CANCER CLUSTER INCUBATOR AS

Royal Norwegian Embassy in Switzerland

THE LIFE SCIENCE CLUSTER

Important conditions

Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.

Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.

Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.